Triptorelin Research Overview (also known as Decapeptyl, Trelstar, GnRH Agonist, HPTA Restart Peptide)
A synthetic GnRH (gonadotropin-releasing hormone) decapeptide agonist used in research as a single-dose HPTA restart protocol following anabolic steroid or SARM suppression. At 100 mcg SubQ, a single pulsatile dose triggers robust LH and FSH release, stimulating endogenous testosterone recovery. Clinical depot forms (3.75 mg IM) achieve the opposite effect — sustained pituitary suppression for prostate cancer treatment.
What Is Triptorelin?
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist — a decapeptide that binds GnRH receptors in the pituitary with significantly higher affinity and longer duration than endogenous GnRH. At low doses administered as a single pulse, triptorelin triggers a robust, physiological LH and FSH surge, which stimulates downstream testosterone production. This mechanism has made it a research tool for HPTA (hypothalamic-pituitary-testicular axis) restart following suppression from anabolic steroid use, SARMs, or other exogenous testosterone — where it is used as a single 100 mcg subcutaneous injection to "reset" the axis.
Mechanism: Pulsatile vs. Continuous Dosing
The paradox of GnRH agonists is dose- and frequency-dependent: a single pulse stimulates gonadotropin release (the desired HPTA restart mechanism), while continuous or depot administration causes GnRH receptor downregulation and pituitary desensitization — the same mechanism used in prostate cancer treatment to achieve medical castration. This is why the research HPTA restart protocol uses a single 100 mcg injection rather than ongoing dosing. Clinical depot forms (3.75 mg IM monthly) achieve the opposite effect and are not relevant to HPTA restart research.
HPTA Restart Research
The single-dose triptorelin HPTA restart protocol (100 mcg SubQ) originated from clinical observations and has been adopted in the research community as an alternative to traditional post-cycle therapy (clomiphene, tamoxifen). The rationale: a single GnRH agonist pulse at the pituitary level resets central suppression more directly than SERMs acting at the hypothalamic level. LH and FSH typically surge within 2–4 hours post-injection, triggering testicular steroidogenesis. Recovery of endogenous testosterone production varies by individual, prior suppression depth, and duration.
Quick Reference
| Literature-Reported Dose Range | 100 mcg SubQ (single dose — HPTA restart) |
| Route | SubQ injection |
| Literature-Reported Cycle Length | Single administration (HPTA restart) |
| Half-Life | ~3–5 hours (aqueous solution) |
| Classification | GnRH Agonist / Hormonal & Sexual |
| Research Status | FDA-approved (depot, prostate cancer) — RUO for HPTA restart |
Research Indications
The primary research application is HPTA axis restoration following suppression by exogenous androgens, SARMs, or other HPT-suppressive compounds. Secondary applications include research into pulsatile GnRH signaling dynamics, male hypogonadotropic hypogonadism, and as a reference compound for studying GnRH receptor pharmacology.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| HPTA Restart (Single Pulse) | 100 mcg | Single injection; optional 2nd at Day 7 if LH/FSH insufficient | SubQ |
Peptide Interactions
Both are GnRH agonists. Combining them provides no additive benefit for HPTA restart and increases the risk of prolonged pituitary receptor downregulation. Use one or the other.
Sequential use is a recognized research approach: triptorelin pulse first (weeks 1–2), followed by 4–6 weeks of Enclomiphene to sustain LH/FSH recovery. Not used simultaneously.
HCG may be used in the weeks following a triptorelin pulse to maintain testicular activity while the HPT axis recovers. Sequential, not concurrent.
Reported Research Timeline
A single low-dose triptorelin injection produces a predictable hormonal arc used by researchers to characterize HPTA recovery. The timeline below reflects the acetate (short-acting) protocol; depot formulations (pamoate/microsphere) produce prolonged suppression and are outside this research context.
- Hours 1–24 (Testosterone Flare): The acute GnRH-driven LH/FSH surge triggers a transient testosterone spike — typically the highest serum testosterone in the protocol window. Transient libido, energy, or mood changes may occur during this phase.
- Days 2–7 (Nadir Phase): After the initial surge, gonadotropins return to baseline. Unlike chronic GnRH agonist protocols, a single dose does not cause pituitary desensitization, so testosterone returns toward prior baseline rather than crashing to castrate levels.
- Weeks 2–4 (Pituitary Recovery): Endogenous LH and FSH begin recovering as the triptorelin effect wanes. Researchers monitoring restart protocols track gonadotropin levels at weeks 2 and 4 to confirm pituitary responsiveness before assessing downstream testosterone output.
- Weeks 4–8 (Testicular Resensitization): Leydig cell testosterone production resumes as gonadotropin signaling re-establishes. Serum testosterone typically recovers toward pre-protocol levels during this window, contingent on baseline Leydig cell function.
- Weeks 8–16 (Normalization): Most published restart research reports baseline testosterone recovery within 90–120 days of the single injection. Values remaining below normal at this point suggest structural gonadal impairment rather than a pituitary-level block.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
CRITICAL: Do not confuse research-use dosing (100 mcg single SubQ) with clinical depot dosing (3.75 mg IM monthly for prostate cancer). Depot doses cause sustained pituitary suppression — the exact opposite of HPTA restart. Confirm vial concentration before dosing.
A testosterone flare (transient rise) may occur 24–72 hours post-injection, followed by the anticipated normalization period. This is expected and not a sign of failure.
Monitor LH, FSH, and total testosterone at baseline (before injection), then at 2 weeks and 6 weeks post-injection to assess axis recovery. Bloodwork is essential — do not assume recovery without lab confirmation.
Not for use in women attempting pregnancy — GnRH agonist pulses carry unpredictable effects on ovarian stimulation outside of a monitored clinical protocol.
Not FDA-approved for HPTA restart — research use only. All information is for educational purposes.
Seek Medical Attention If:
Testosterone flare symptoms: worsening bone pain, urinary obstruction, or neurological changes
Signs of allergic or hypersensitivity reaction to any injection
Severe or unusual symptoms in the days following administration
Always consult a licensed physician — use only short-acting formulations for restart protocols
Quality Indicators
Expected
HPLC Purity ≥ 98%
Certificate of Analysis confirming ≥98% purity by HPLC is standard for RUO triptorelin acetate. Reject suppliers who cannot provide this.
Expected
Mass Spec Sequence Verification
Confirm molecular weight (~1311 Da for triptorelin acetate) by LC-MS/MS. Differentiates from depot formulations.
Expected
Short-Acting Formulation Only
Research protocols use triptorelin acetate (short-acting), NOT pamoate or microsphere depot formulations, which cause sustained suppression.
Expected
Sterility & Endotoxin Testing
LAL endotoxin test result and sterility certificate should accompany any injectable research compound.
Research Citations
Frequently Asked Questions
What should researchers watch for with Triptorelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Triptorelin?
A single low-dose triptorelin injection produces a predictable hormonal arc used by researchers to characterize HPTA recovery. The timeline below reflects the acetate (short-acting) protocol; depot formulations (pamoate/microsphere) produce prolonged suppression and are outside this research context.
How is Triptorelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →